Analytical Data
-
基因名
CD37
- Application
-
别名
Tetraspanin-26; Tspan-26; CD37; CD37 molecule; GP52-40; MGC120234
-
种属
Human
-
表达系统
E. coli
-
标签
N- His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P11049
-
表达区间
1-281aa
-
分子量
34.5 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD37 is a tetraspanin protein that plays a crucial role in the immune system, particularly in the regulation of B cell activation and differentiation. It is predominantly expressed on various immune cells, including B cells, monocytes, and macrophages. Dysregulation or aberrant expression of CD37 has been implicated in several hematological malignancies, including lymphomas and leukemias, making it a potential target for therapeutic interventions. Researchers have focused on the production of recombinant CD37 protein to elucidate its structural and functional properties. This recombinant protein allows for detailed studies of CD37's role in immune signaling pathways and its interactions with other surface proteins. Additionally, the generation of CD37-targeted therapies, such as monoclonal antibodies or CAR T-cell approaches, holds promise for the treatment of CD37-expressing tumors. The ongoing investigation into CD37 not only enhances our understanding of immune regulation but also paves the way for novel immunotherapeutic strategies aimed at improving patient outcomes in CD37-associated malignancies.
